QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 0.6601
-- x --
-- x --
-- - --
$ 0.55 - $ 4.56
574,675
na
10.41M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-20-2023 09-30-2023 10-Q
2 08-14-2023 06-30-2023 10-Q
3 05-15-2023 03-31-2023 10-Q
4 03-27-2023 12-31-2022 10-K
5 11-14-2022 09-30-2022 10-Q
6 08-15-2022 06-30-2022 10-Q
7 05-16-2022 03-31-2022 10-Q
8 03-02-2022 12-31-2021 10-K
9 11-19-2021 09-30-2021 10-Q
10 08-10-2021 06-30-2021 10-Q
11 05-17-2021 03-31-2021 10-Q
12 03-01-2021 12-31-2020 10-K
13 11-10-2020 09-30-2020 10-Q
14 08-13-2020 06-30-2020 10-Q
15 05-14-2020 03-31-2020 10-Q
16 03-18-2020 12-31-2019 10-K
17 11-13-2019 09-30-2019 10-Q
18 08-13-2019 06-30-2019 10-Q
19 05-14-2019 03-31-2019 10-Q
20 03-07-2019 12-31-2018 10-K
21 11-09-2018 09-30-2018 10-Q
22 08-13-2018 06-30-2018 10-Q
23 05-14-2018 03-31-2018 10-Q
24 03-07-2018 12-31-2017 10-K
25 11-13-2017 09-30-2017 10-Q
26 08-14-2017 06-30-2017 10-Q
27 05-12-2017 03-31-2017 10-Q
28 03-28-2017 12-31-2016 10-K
29 11-14-2016 09-30-2016 10-Q
30 08-11-2016 06-30-2016 10-Q
31 05-12-2016 03-31-2016 10-Q
32 03-15-2016 12-31-2015 10-K
33 11-10-2015 09-30-2015 10-Q
34 08-12-2015 06-30-2015 10-Q
35 05-12-2015 03-31-2015 10-Q
36 02-23-2015 12-31-2014 10-K
37 11-06-2014 09-30-2014 10-Q
38 08-14-2014 06-30-2014 10-Q
39 05-14-2014 03-31-2014 10-Q
40 02-27-2014 12-31-2013 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bayers-third-menopausal-relief-drug-trial-meets-primary-goal-german-conglomerate-seeks-fda-approval-for-elinzanetant

Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Resu...

 hc-wainwright--co-downgrades-acer-therapeutics-to-neutral

HC Wainwright & Co. analyst Vernon Bernardino downgrades Acer Therapeutics (NASDAQ:ACER) from Buy to Neutral.

 why-olin-are-trading-lower-by-13-here-are-other-stocks-moving-in-fridays-mid-day-session

Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) surged 181.1% to $3.63. TradeUP Acquisition Corp. (NASDAQ: UPTD) gaine...

 roth-capital-downgrades-acer-therapeutics-to-neutral-maintains-15-price-target

Roth Capital analyst Jonathan Aschoff downgrades Acer Therapeutics (NASDAQ:ACER) from Buy to Neutral and maintains $1.5 pric...

 why-dell-technologies-shares-are-trading-higher-by-9-here-are-20-stocks-moving-premarket

Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) rose 53.4% to $0.2147 in pre-market trading after the company announce...

 roth-mkm-downgrades-acer-therapeutics-to-neutral-announces-15-price-target

Roth MKM analyst Jonathan Aschoff downgrades Acer Therapeutics (NASDAQ:ACER) from Buy to Neutral and announces $1.5 price ta...

 dow-tumbles-over-100-points-acer-therapeutics-shares-spike-higher

U.S. stocks traded mixed toward the end of trading, with the Dow Jones falling more than 100 points on Thursday. The Dow trade...

 why-lands-end-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session

Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra Therapeutics announced it will acqu...

 nasdaq-rises-50-points-dollar-general-shares-slide

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 50 points on Thursday. The Dow trad...

 us-stocks-rise-initial-jobless-claims-edge-lower

U.S. stocks traded higher this morning, following the release of economic reports. Following the market opening Thursday, the ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION